NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window30-06-2022
NATCO PHARMA LTD. - 524816 - Disclosure Of Related Party Transactions For The Half Year Ended 31 March, 2022
Disclosure of Related Party Transactions for the half year ended 31 March, 202213-06-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q4 FY22 Investor Presentation07-06-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 FY 2022 Earnings Call Transcript04-06-2022
Natco Pharma launches first generic of Nexavar in the US
The product will be launched by Hyderabad-based Natco Pharma's commercial partner, Viatris01-06-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO Announces Launch of First Generic Version of Nexavar(r) (Sorafenib) Tablets in the U.S. Market01-06-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Recording of Analysts/Institutional Investor Meet/Con. Call held on 31st May, 202231-05-2022
Earnings Call for Q4FY22 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.31-05-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News paper publication of Audited Results for the quarter and year ended 31st March 202231-05-2022